[go: up one dir, main page]

SV1999000026A - STATIN-MMP INHIBITOR COMBINATIONS - Google Patents

STATIN-MMP INHIBITOR COMBINATIONS

Info

Publication number
SV1999000026A
SV1999000026A SV1999000026A SV1999000026A SV1999000026A SV 1999000026 A SV1999000026 A SV 1999000026A SV 1999000026 A SV1999000026 A SV 1999000026A SV 1999000026 A SV1999000026 A SV 1999000026A SV 1999000026 A SV1999000026 A SV 1999000026A
Authority
SV
El Salvador
Prior art keywords
statin
mmp inhibitor
inhibitor combinations
combinations
mmp
Prior art date
Application number
SV1999000026A
Other languages
Spanish (es)
Inventor
Newton Roger Schofield
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SV1999000026A publication Critical patent/SV1999000026A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA CON UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE MMP Y UNA ESTATINA, DICHA COMPOSCCION ES UTIL PARA TRATAR ENFERMEDADES VASCULARES.THE PRESENT INVENTION IS RELATED TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN MMP INHIBITOR AND A STATIN, SUCH A COMPOSTION IS USEFUL FOR TREATING VASCULAR DISEASES.

SV1999000026A 1998-03-17 1999-03-16 STATIN-MMP INHIBITOR COMBINATIONS SV1999000026A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
SV1999000026A true SV1999000026A (en) 2000-01-18

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1999000026A SV1999000026A (en) 1998-03-17 1999-03-16 STATIN-MMP INHIBITOR COMBINATIONS

Country Status (18)

Country Link
EP (1) EP1063991A1 (en)
JP (1) JP2002506818A (en)
KR (1) KR20010041916A (en)
AR (1) AR018113A1 (en)
AU (1) AU1591699A (en)
BR (1) BR9815745A (en)
CA (1) CA2309588A1 (en)
CO (1) CO5070670A1 (en)
GT (1) GT199900039A (en)
HN (1) HN1999000029A (en)
MY (1) MY140504A (en)
NZ (1) NZ505994A (en)
PA (1) PA8469001A1 (en)
PE (1) PE20000348A1 (en)
SV (1) SV1999000026A (en)
UY (1) UY25436A1 (en)
WO (1) WO1999047138A1 (en)
ZA (1) ZA992106B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
CN101080232A (en) 2004-12-15 2007-11-28 索尔瓦药物有限公司 Pharmaceutical composition comprising NEP-inhibitor, inhibitor of endogenous endothelin production system and HMG CoA reductase inhibitor
JP2009514851A (en) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド (3R, 5R) -7- [2- (4-Fluorophenyl) -5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino) carbonyl] -pyrrol-1-yl] -3,5 -Preparation of dihydroxy-heptanoic acid hemi-calcium salt
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU720853B2 (en) * 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
EE03965B1 (en) * 1996-05-17 2003-02-17 Warner-Lambert Company Matrix metalloproteinase biphenylsulfonamide inhibitors
KR20000057444A (en) * 1996-12-09 2000-09-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Method for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (en) * 1997-08-29 2000-01-29 COMBINATION THERAPY.

Also Published As

Publication number Publication date
WO1999047138A1 (en) 1999-09-23
BR9815745A (en) 2000-11-14
JP2002506818A (en) 2002-03-05
HN1999000029A (en) 1999-09-29
PE20000348A1 (en) 2000-05-22
CA2309588A1 (en) 1999-09-23
ZA992106B (en) 1999-09-30
MY140504A (en) 2009-12-31
GT199900039A (en) 2000-09-06
UY25436A1 (en) 2001-10-25
NZ505994A (en) 2003-10-31
CO5070670A1 (en) 2001-08-28
AU1591699A (en) 1999-10-11
KR20010041916A (en) 2001-05-25
PA8469001A1 (en) 2002-09-17
EP1063991A1 (en) 2001-01-03
AR018113A1 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
BR9809819A (en) Compounds and methods for inhibiting vcam-1 expression
BR0113669A (en) Deacetylase Inhibitors
BR0113661A (en) Pharmaceutical compositions for the topical release of cyclooxygenase-2 enzyme inhibitors
EA199900373A2 (en) PHARMACEUTICAL COMPOSITIONS
ES2148345T3 (en) PHARMACEUTICAL COMPOSITION WITH CYCLOSPORINE A, A DERIVATIVE OF VITAMIN E AND AN EMULSIONANT.
AR015379A1 (en) ASCORBIL-FOSFORIL-CHOLESTEROL
HN2001000146A (en) PIRAZOL DERIVATIVES
ES2178298T3 (en) ANTI-INFLAMMATORY COMPOUNDS.
PA8506101A1 (en) USE OF AN ACAT COMPOUND TO MANUFACTURE A PHARMACEUTICAL COMPOSITION
DE69810328D1 (en) COMPILATION OF MIXED CYANOACRYLATE ESTERS
ES2164182T3 (en) BENZOCICLOPENTANOXAZOLIDINONES THAT CONTAIN HETEROATOMOS WITH ANTIBACTERIAL ACTIVITY.
PT1105122E (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LIPASE INHIBITORS
UY25714A1 (en) METHOD FOR TREATING ATHEROSCLEROSIS USING AN AP2 INHIBITOR AND COMBINATION.
ES2182874T3 (en) NAIL TREATMENT PROCEDURE.
PT1032414E (en) COMBINATION OF AN INHIBITOR OF THE ANGIOTENSIN CONVERSATION ENZYME AND A DIURETIC FOR THE TREATMENT OF MICROCIRCULATORY DISTURBACTIONS
AU2003296807A1 (en) Cosmetic composition comprising a metalloproteinase inhibitor and a lipopeptide
ES2184340T3 (en) COMBINATIONS OF INHIBITORS OF THE ANGIOTENSIN CONVERSION ENZYME AND INHIBITORS OF THE MATRIX METALOPROTEINASE ENZYME.
MEP64008A (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
DK1105114T3 (en) Nimesulide-containing topical pharmaceutical compositions
BR9910539A (en) Derivatives of 2 - (2 - chlorophenyl) - 3,4 - dihydro - 2h - pyrrole
BR0213181A (en) Cox-2 inhibitor combinations
ES2176714T3 (en) DEODORANT PREPARATIONS.
SE9801494D0 (en) Novel use
CU20000140A7 (en) STATIN-CARBOXIALQUILETER COMBINATIONS
ES2132539T3 (en) SYNERGIC INSECTICIDE COMPOSITIONS.

Legal Events

Date Code Title Description
FG Grant
FD Lapse